Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Allergan gets US nod for Inamed merger:

This article was originally published in Clinica

Executive Summary

Allergan has cleared its final regulatory hurdle to closing its acquisition of Inamed, following yesterday's green light from the US Federal Trade Commission. Irvine California-based Allergan now expects to complete its exchange offer for outstanding shares of the breast implant maker by Friday (March 10) and to close the deal immediately after. Allergan agreed to buy the fellow Californian company in December last year for $84 per share in cash or 0.8498 of Allergan stock.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT051105

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel